Budget impact analysis of a digital monitoring platform for COPD

Cost Effectiveness and Resource Allocation

Research

Umur Hatipoğlu¹  Timothy J. Inocencio²  Sibel Sayiner³  Leanne Kaye⁴  Michael E. Minshall⁴  Kimberly L. Sterling⁴ 

[1] Cleveland Clinic, Cleveland, OH, USA;Open Health Evidence and Access, Parsippany, NJ, USA;Propeller Health, San Francisco, CA, USA;ResMed Science Center, 9001 Spectrum Center Boulevard, 92123, San Diego, CA, USA;

关键词: Chronic obstructive pulmonary disease;    Cost;    Remote monitoring;    Digital health technology;    Budget impact;   

DOI  :  10.1186/s12962-023-00443-x

 received in 2022-03-31, accepted in 2023-05-18,  发布年份 2023

来源: Springer

【 摘 要 】

BackgroundChronic obstructive pulmonary disease (COPD) is a progressive debilitating condition with frequent exacerbations that have a high burden for patients and society. Digital tools may help to reduce the economic burden for patients and payers by improving outcomes. The Propeller platform is a digital self-management tool that facilitates passive monitoring of inhaler medication utilization, potentially assisting the healthcare team to identify patients at risk of a COPD exacerbation who may require further intervention. This study estimated the budget impact of Propeller from commercial payer and Medicare fee-for-service payer perspectives.MethodsAn Excel-based model was used to estimate the budget impact of Propeller for COPD patients in commercial and Medicare population sizes of 5 million members. Data on prevalence, baseline healthcare resource utilization (HCRU), and baseline use of rescue and controller inhaler medications with unit costs (adjusted to 2020 US dollars) were obtained from peer-reviewed literature. Data on reductions in HCRU during Propeller usage were based on direct evidence. Estimates for costs of remote monitoring were obtained from publicly available information. All patients were assumed to have insurance claims related to ongoing remote monitoring.ResultsThe estimated number of annual eligible COPD patients for commercial and Medicare was 212,200 and 606,600, respectively. Propeller decreased costs by an estimated $2,475 (commercial) and $915 (Medicare) per enrolled patient. The greatest increase in expenditure was for remote monitoring related expenses. After accounting for estimated reductions in hospitalizations, emergency department visits and short-acting beta-agonist use, total net savings were approximately $1.60 and $1.70 per-member per-month for commercial and Medicare payers, respectively.ConclusionPropeller is projected to be cost saving from both the commercial and Medicare payer perspectives.

【 授权许可】

CC BY   
© The Author(s) 2023